Open Beta
TREN
MetriLume
TREN

US marketsNRXP

SEC-sourced researchBeta

NRXP

NRX Pharmaceuticals, Inc.

Company comparison ↗

Data passport

CIK
0001719406
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 5, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 0.0000 USD; December 2025: 1,225,000.0000 USD1.2M USD0 USD0December 2024December 2025
NRXP · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20240.0000Mar 23, 2026
December 20251,225,000.0000Mar 23, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 20251,225,000.0000-28,622,000.0000-14,112,000.000012,956,000.000028,893,000.0000Mar 23, 2026
December 20240.0000-25,126,000.0000-10,637,000.00003,651,000.000026,874,000.0000Mar 23, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$1.23MDecember 2025Mar 23, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$0December 2024Mar 23, 202610-K
Net incomeNetIncomeLoss-$28.62MDecember 2025Mar 23, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$14.11MDecember 2025Mar 23, 202610-K
Total assetsAssets$12.96MDecember 2025Mar 23, 202610-K
Total liabilitiesLiabilities$28.89MDecember 2025Mar 23, 202610-K

New filings

Explore methodology ↗